MedPath

VyLibra

These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra  (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989

Approved
Approval ID

13bdc226-ecf8-4fd7-aa0e-ec19b6b74fc3

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 13, 2023

Manufacturers
FDA

Afaxys Pharma, LLC

DUNS: 080508656

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

norgestimate and ethinyl estradiol

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50102-235
Application NumberANDA205449
Product Classification
M
Marketing Category
C73584
G
Generic Name
norgestimate and ethinyl estradiol
Product Specifications
Effective DateApril 13, 2023
FDA Product Classification

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

VyLibra - FDA Drug Approval Details